This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tilray Gains More Than 200%: Is There More Scope for Growth?
by Zacks Equity Research
Tilray (TLRY) gains more than 200% in the past six months. Strategic deals should propel further growth.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $28.23 in the latest trading session, marking a +0.43% move from the prior day.
Upcoming Earnings to Watch: LEN, STZ, BBBY
by Ryan McQueeney
Stocks whipsawed this week, just in time for the first wave of earnings reports to help motivate the direction of the market. Let's take a closer look at a few of the earnings announcements due during the week of January 7.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $27.34, moving +1.98% from the previous trading session.
AB InBev (BUD) Enters Booming Cannabis Realm With Tilray Deal
by Zacks Equity Research
AB InBev (BUD) announces partnership with the leading marijuana producer, Tilray.
Tilray Stock Up on Medical Cannabis Collaboration With Sandoz
by Zacks Equity Research
Tilray (TLRY) expands its previous collaboration deal with Sandoz, a generic arm of Novartis, to supply medical cannabis globally using the latter's supply chain.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $29.21, marking a -0.54% move from the previous day.
4 Reasons Why Pot Stocks & ETF Could Be on a High in 2019
by Sanghamitra Saha
These are the factors that could send marijuana stocks and ETF high in 2019.
3 Pot Stocks to Watch on Farm Bill & News from Trump, May, Retail Earnings
by Ryan McQueeney
Ryan McQueeney discusses President Trump's latest comments on the trade war and the impending vote of confidence facing U.K. Prime Minister Theresa May. He also recaps earnings results from the retail sector. Later, he highlights three cannabis stocks to watch as the farm bill passes.
Highlighted as Zacks Bull and Bear of the Day AeroVironment, Beacon Roofing Supply, Canopy Growth and Constellation
by Zacks Equity Research
Highlighted as Zacks Bull and Bear of the Day AeroVironment, Beacon Roofing Supply, Canopy Growth and Constellation
Canopy Growth (CGC) Gains on Hemp Legalization, Institutional Interest
by Ryan McQueeney
Shares of Canopy Growth (CGC) were up more than 6% in late afternoon trading Tuesday, as investors expressed optimism about the Senate's hemp legalization bill and management's comments about interest from institutional investors.
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
Cronos Group (CRON) Soars on C$2.4B Investment from Altria
by Zacks Equity Research
Cronos Group (CRON) receives a significant boost with C$2.4-billion equity investment from tobacco giant Altria Group.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $31.02, moving -1.21% from the previous trading session.
Here's Why You Should Hold Constellation Brands Stock Now
by Zacks Equity Research
Constellation Brands (STZ) is a favored stock, owing to its robust surprise trend, strength in the beer business and solid business growth plans, including investment in Canopy Growth.
Cronos-Altria Deal Boost Marijuana ETF: Will This Continue?
by Sweta Killa
Altria investment in Canadian cannabis producer Cronos sparked a rally in the broad cannabis sector and the its ETF. Will the trend continue?
Are Options Traders Betting on a Big Move in Canopy Growth (CGC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Are There Any Dividend-Paying Cannabis Stocks?
by Ryan McQueeney
Cannabis stocks have been one of the investing world's top stories in 2018, but for many, these speculative plays are far too unpredictable. Are there any stable, dividend-paying marijuana stocks to buy right now?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $33.33 in the latest trading session, marking a -0.66% move from the prior day.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $31.70 in the latest trading session, marking a +0.48% move from the prior day.
Legal Pot Shops & Likely IPOs: Is Hemp the Next Big Thing?
by Nitish Marwah
Increasing tolerance and gradual legalization of marijuana has been an increasing trend across America.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Inside the winning and losing ETFs of the last week.
Company News For Nov 15, 2018
by Zacks Equity Research
Companies In The News Are: CGC,GOOS,SNAP,PENN
What Went Wrong With the Marijuana ETF on Wednesday?
by Sanghamitra Saha
Downbeat earnings have weighed on the marijuana ETF lately. Should you buy the dip or wait on the sidelines?
Canopy Growth Corporation (CGC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -484.62% and -30.27%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?